Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Income from Continuing Operations (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Income from Continuing Operations for 4 consecutive years, with 54891000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 28.96% to 54891000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 242698000.0, a 50.5% decrease, with the full-year FY2024 number at 235757000.0, down 56.04% from a year prior.
  • Income from Continuing Operations was 54891000.0 for Q3 2025 at Centessa Pharmaceuticals, down from 50343000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 24886000.0 in Q2 2023 to a low of 111329000.0 in Q4 2024.
  • A 4-year average of 48961200.0 and a median of 43816000.0 in 2024 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 61.51% in 2023, then crashed 202.22% in 2024.
  • Centessa Pharmaceuticals' Income from Continuing Operations stood at 43173000.0 in 2022, then increased by 14.68% to 36837000.0 in 2023, then plummeted by 202.22% to 111329000.0 in 2024, then skyrocketed by 50.69% to 54891000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Income from Continuing Operations are 54891000.0 (Q3 2025), 50343000.0 (Q2 2025), and 26135000.0 (Q1 2025).